Curriculum Vitae
SAMUEL LEONARD STANLEY JR., M.D.
PRESENT POSITION
President, Michigan State University
PERSONAL INFORMATION
Place of birth: Seattle, Washington
Spouse: Ellen Li, M.D., Ph.D.
CITIZENSHIP
USA
ADDRESS
Office of the President
Michigan State University
426 Auditorium Road
Hannah Administration Building, Room 450
East Lansing, MI 48824-1046
Email: presmail@msu.edu
Phone: (517) 355-6560
EDUCATION
| Year(s) | Education |
|---|---|
| 1976 | B.A., Biological Sciences, The College of the University of Chicago, IL |
| 1980 | M.D., Medicine, Harvard University Medical School, Cambridge, MA |
| 1984-1987 | Postdoctoral, Immunology, Washington University School of Medicine, St. Louis, MO |
ACADEMIC POSITIONS/EMPLOYMENT
| Year(s) | Position |
|---|---|
| 1976 | Teaching Assistant in Biology, The College of the University of Chicago, IL |
| 1980-1981 | Medical Intern, Massachusetts General Hospital, Boston, MA |
| 1981-1983 | Medical Resident, Massachusetts General Hospital, Boston, MA |
| 1983-1984 | Fellow in Infectious Diseases, Washington University School of Medicine, St. Louis, MO |
| 1985-1988 | Pfizer Fellow in Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO |
| 1987-1988 | Instructor in Medicine, Washington University School of Medicine, St. Louis, MO |
| 1988 | Assistant Professor, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO |
| 1989 | Assistant Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO |
| 1990-2009 | Chief Medical Consultant, BarnesCare Travelers Clinic |
| 1993-1999 | Associate Professor (with tenure), Department of Medicine, Washington University School of Medicine, St. Louis, MO |
| 1994-2004 | Associate Professor, Department of Molecular Microbiology |
| 1999-2009 | Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO |
| 2003-2009 | Director, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research |
| 2004-2009 | Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO |
| 2006-2009 | Vice Chancellor for Research, Washington University in Saint Louis, MO |
| 2009-2019 | Professor of Medicine, Stony Brook University School of Medicine, Stony Brook, NY |
| 2009-2019 | President, Stony Brook University, Stony Brook, NY |
| 2019- | Professor of Medicine, Michigan State University College of Human Medicine, East Lansing, MI |
| 2019- | President, Michigan State University, East Lansing, MI |
UNIVERSITY AND HOSPITAL APPOINTMENTS AND COMMITTEES
| Year(s) | Appointment |
|---|---|
| 1987-2006 | Attending physician, Internal Medicine and Infectious Diseases, Barnes-Jewish Hospital of St. Louis |
| Chief Medical Consultant, BarnesCare Travelers Clinic | |
| 1989 | Chairman, Committee to Formulate a Health Policy for Washington University Personnel Who Work with Animals |
| 1992-2000 | Member, Washington University MA/MD Committee |
| 1992-2001 | Program Committee, American Society of Tropical Medicine and Hygiene |
| 1995-1997 | At-large Representative Washington University Faculty Senate |
| Member, Senate Council of Washington University | |
| Member, Advisory Committee on Academic Freedom and Tenure | |
| 1997-1999 | Faculty Representative, Washington University Benefits Committee |
| 1999-2004 | Selection Committee and Advisory Board Medical Student International Fellowships |
| 2000-2002 | Clinical Representative to the Executive Faculty, Washington University School of Medicine |
| 2000-2004 | Chairman, Institutional Biological and Chemical Safety Committee |
| 2001-2002 | Division of Biology and Biomedical Sciences Graduate Admissions Committee |
| 2006-2008 | Chairman, Research Strategic Planning for Washington University School of Medicine |
| 2007-2009 | Chairman, Skandalaris Center Research Planning Committee |
| 2009-2019 | Governing Body, Stony Brook University Hospital, Stony Brook NY |
MEDICAL LICENSURE AND BOARD CERTIFICATION
Massachusetts License 1980-83
Missouri License 1983-present
American Board of Internal Medicine, Certification in Internal Medicine 1983
American Board of Internal Medicine, Certification in Infectious Diseases 1986
MILITARY SERVICE
None
HONORS AND AWARDS
| Year(s) | Honor/Award |
|---|---|
| 1976 | Honors in Biological Sciences, University of Chicago |
| 1976 | Phi Beta Kappa, University of Chicago |
| 1979 | Albert Schweitzer Fellow of Harvard Medical School |
| 1985-1988 | Pfizer Postdoctoral Fellow |
| 1994-1999 | Research Career Development Award, NIH |
| 1999-2004 | Burroughs-Wellcome Scholar in Molecular Parasitology |
| 2000 | Distinguished Service Teaching Award — Washington University School of Medicine |
| 2002-2004 | Permanent member, Tropical Medicine and Parasitology Study Section |
| 2004-2006 | Permanent member, Eukaryotic Pathogenesis Study Section |
| 2005-2006 | Excellence in Mentoring, Washington University School of Medicine |
| 2006 | Distinguished Service Award, Washington University Medical Center Alumni Association |
| 2007-2008 | Ambassador, Paul G. Rogers Society for Global Health Research |
| 2009 | Honorary Doctorate Degree, Konkuk University, Seoul, Korea |
| 2009 | Honoree, VIBS (Victims Information Bureau of Suffolk) |
| 2010 | Long Island Association Small Business Education Advocate Award |
| 2010 | Thomas Hartman Humanitarian Award |
| 2010 | The Influentials: “Long Island Business News” Top 20 Agents of Change |
| 2012 | Three Village Man of the Year |
| 2012, 2013, 2015, 2016 | “Long Island Press,” Best College President |
| 2013 | David Award Honoree |
| 2014 | EOP (Educational Opportunity Program) Champion |
| 2014 | American Heart Association Distinguished Leadership Honoree |
COMMUNITY AND REGIONAL RESPONSIBILITIES
| Year(s) | Position |
|---|---|
| 2006-2009 | Board of Directors, Center for Emerging Technologies |
| 2006-2009 | Board Member, Research Alliance of Missouri |
| 2006-2009 | Board of Trustees, Saint Louis Academy of Science |
| 2007-2009 | Board Member, St. Louis Center of Excellence, Missouri Life Sciences Trust Fund |
| 2009-2017 | Board of Trustees, Cold Spring Harbor Laboratory |
| 2009-2017 | Board of Directors, Goodwill Industries of Greater NY and Northern NJ |
| 2009-2018 | Board of Directors, The Research Foundation of SUNY |
| 2009-2019 | Board of Directors, Long Island Association |
| 2010- | Education Working Group member for United States Senator Kirsten Gillibrand |
| 2011 | Health and Education Transition Committee member for NY Governor Andrew Cuomo |
| 2011-2019 | Long Island Regional Economic Development Council |
| 2012-2019 | Board of Directors, Accelerate Long Island |
| 2013-2019 | Board of Directors, New York Genome Center |
| 2014-2017 | Chair, Long Island Regional Advisory Council on Higher Education |
NATIONAL BOARDS AND PANELS
National Science Advisory Board for Biosecurity (NSABB), Criteria Roundtable Adviser, June 2006
NIH Blue Ribbon Panel on the National Emerging Infectious Diseases Laboratories, 2008-2010
NIH National Advisory Allergy & Infectious Diseases Council, 2008-2012
US Department of Commerce, Emerging Technology and Research Advisory Committee, 2008-2010
Chair, Board of Directors, Brookhaven Science Associates, 2009-2019
National Security Higher Education Advisory Board, 2011-2018
Chair, National Science Advisory Board for Biosecurity (NSABB), 2012-2018
Association of Public and Land-Grant Universities, Board of Directors, 2012-2016, 2019-
Association of Public and Land-Grant Universities, Research Intensive Committee, Vice Chair, 2017-
Chair, America East Conference Board of Presidents, 2012-2015
America East Conference Board of Presidents, 2009-2019
Chair, Universities Research Association Council of Presidents, 2014-2015
National Collegiate Athletic Association (NCAA) Division I Board of Directors, 2014-2018
National Collegiate Athletic Association (NCAA) Division I Board of Governors, 2016-2018
Association of Public and Land-Grant Universities, Research Intensive Committee, Vice Chair, 2016-2018, Chair 2019-
UNWomen HeForShe Champion: One of 10 university leaders worldwide (and one of the two in the United States) appointed by UNWomen as Global Champions
NCAA Board of Directors Pathway Program Presidential Mentor, 2017-2019
NCAA Board of Governors Student Athlete Engagement Committee, 2017-2018
Association of American Universities Board of Directors, 2017-
NIH Advisory Committee to the Director, Working Group on Foreign Influences on Research Integrity, 2018-2019
PROFESSIONAL SOCIETIES AND ORGANIZATIONS
Associate Member, American College of Physicians, 1981
Member, American Society of Tropical Medicine and Hygiene, 1988
Member, Infectious Disease Society of America, 1989
Member, American Federation for Clinical Research, 1989
Member, American Society for Microbiology, 1992
Fellow, Infectious Disease Society of America, 1995
Member, American Society for Clinical Investigation, 1995
Secretary-Treasurer, Board of Directors, Infectious Diseases Society of St. Louis, 2004-2007
EDITORIAL AND REVIEW RESPONSIBILITIES
Editorial Board:
Infection and Immunity 1998-2003
Ad hoc reviewer for:
New England Journal of Medicine
Clinical Infectious Diseases
Journal of Infectious Diseases
Molecular Microbiology
Gastroenterology
Physiological Reviews
Cellular Microbiology
PNAS
Acta Tropica
Vaccine
Parasite Immunology
Experimental Parasitology
Lancet
Journal of Parasitology
Am.J.Tropical Medicine and Hygiene
Laboratory Animal Science
Molecular and Biochemical Parasitology
Nature
Ad hoc grant reviewer for:
Wellcome Trust
International Center for Diarrhoeal Disease Research
USAID
American Federation for AIDS Research NIH—SEPs on TDRU program
Temporary member: NIH-TMP study section 10-2000, 6-2002
EpScor NSF Site Visit Team 2005
Educational Accreditation:
Chair, University of California, Santa Cruz accreditation team for Western Association of Schools & Colleges (WASC), 2015
OPINION EDITORIALS AND ESSAYS
Newsday: Stanley: Protect research institutions from sequestration – and beyond, October 2012
Newsday: How will the sequester affect you? Long Island Institutions respond, February 2013
Huffington Post: College Cost and Student Loan Debt, June 2013
Huffington Post: Federal Investment in Research Still Essential April 2014
Huffington Post: 70 Years After the GI Bill, We Need a Similar Investment, June 2014
Newsday: A sure way to attack deadly Ebola, September 2014
Huffington Post: Protect and Maintain America's Scientific Preeminence, December 2014
Huffington Post: Investing in America's Dazzling Scientific Talent, December 2014
Huffington Post: How Best to Hold Federal Scientific Research Accountable, January 2015
Huffington Post: The Changing Politics and Consistent Science of Vaccinations, March 2015
Scientific American: Give Young Scientists the Keys to the Lab, October 2015
Huffington Post: HeForShe Comes to Campus, April 2016
Huffington Post: Fixing Our National Infrastructure Requires Fixing Our Science Infrastructure, October 2016
Scientific American: Anti-Immigration Rhetoric Is a Threat to American Leadership, March 2017
Inside Higher Ed: Focus on Economic Mobility, January 2018
Chronicle of Higher Education: How to Help Combat Global Warming, Campus by Campus, August 2018
MAJOR INVITED LECTURES
Visiting scientist and lecturer — Centro de Investigacion y de Estudios Avanzados del IPN, Mexico City, Mexico, March 1991
Speaker — “Molecular approach to Entamoeba histolyticapathogenesis,” St. Louis University, April 1991
Chair — Amebiasis Session, American Society Tropical Medicine Hygiene — “Isolation of an Entamoeba histolyticacDNA clone encoding a protein with a zinc finger domain,” Boston, November, 1991
Keynote Speaker — “Role of the amebic cysteine proteinase in amebic liver abscess formation.” Meeting of the Society of Biological Chemistry (Mexico), Zacetecas, Mexico, November 1994
Co-chair and Speaker — Merck Symposium on Amebiasis — “New models for amebiasis.” ASTMH Meetings, Cincinnati, November 1994
Speaker — “Scid mouse model of amebiasis” and “Scid mice and gene knockout mice as models for parasitic disease.” India/USA. Joint Vaccine Action Program, Lucknow, India, December 1994
Speaker — “What can murine models tell us about the immunobiology of amebiasis?” Berne Immunology Center, University of Virginia, Charlottesville, December 1994
Speaker — “Progress in a vaccine for amebiasis.” European Conference on Tropical Medicine, Hamburg, November 1995
Chair and Speaker — Symposium — New insights into the immunobiology of parasitic diseases from knockout and scid mice. ASTMH Meeting, December 1996
Speaker — Bernardo Sepulveda Molecular Biology Seminar, XIII Congress on Amebiasis, Mexico City, Mexico, January 1997
Speaker — Keystone Symposium on Cellular and Molecular Cross Talk at Mucosal Surfaces, Santa Fe, New Mexico, March 1997
Speaker — “EhADH2 enzyme: A novel target for anti-amebic drugs.” ICTDR Conference, Washington, DC, April 1997
Speaker — “Oral and DNA vaccines to prevent amebiasis.” ICTDR Conference, Washington, DC. April 1998
Speaker — “How intestinal epithelial cells regulate the inflammatory response to enteric pathogens.” University of Texas Health Sciences Center, San Antonio, Texas, June 1998
Visiting professor and Speaker — “Amebiasis: Putting man into mouse to understand an ancient enemy.” New York University Medical Center Grand Round, January 1999
Speaker — “Pathways for amebic induction of inflammation and programmed cell death,” Burroughs Wellcome
Symposium, ASTMH Meeting, Washington, DC, November 1999
Speaker — “Pathways for amoebic induction of inflammation and tissue damage.” International
Symposium on Amoebiasis. Hamburg, Germany, July 2000
Speaker — National Institutes of Health/National Institute for Allergic and Infectious Diseases, “Amebic dysentery and ICE,” April 2001
Speaker — St. Louis University, “Amebic dysentery and ICE,” September, 2001
Speaker — University of Texas at El Paso, “Amebic dysentery and ICE,” October 2001
Speaker — Southern Illinois University at Carbondale, “Amebic dysentery and ICE,” October 2001
Speaker — Washington University School of Medicine, Department of Pediatrics Grand Rounds, “Amebiasis — New insights into an ancient enemy,” October, 2001
Chairman and Speaker: Session on Amebiasis: Ellison Foundation Conference on Tropical Diseases, Bhubaneswar, India, February 2002
Speaker — Woods Hole Tropical Medicine and Parasitology Course: “Amebiasis”, July 2002, July 2003.
Speaker — Plenary Session, X International Conference on Parasitology, Vancouver, B.C. “Pathways for amebic induction of inflammation and programmed cell death,” August 2002.
Speaker — Special Symposium in Honor of Jean Hickman: “New insights into amebiasis from SCID-HU-INT mice.” ASTMH meeting, Denver, November 2002
Speaker — “Role of TNF in amebic induced inflammation.” EMBO Conference on Amebiasis, Paris, France, March 2003
Speaker — Engineering Connections Series — “SARS and other emerging infectious diseases — the dangers of a small world.” Washington University, September 2003
Speaker — Yonsei University, Challenges in the Post Genomic Era: “Simultaneous host/pathogen genomics,” November 2003
Speaker — Korean Society of Parasitology: “Pathways for amebic induction of inflammation and programmed cell death,” November 2003
Speaker — Institute Pasteur: “New insights into dysentery from SCID-HU-INT mice,” November 2003
Speaker — University of Illinois, Emerging Infectious Diseases Conference: “Pathogenesis of amebiasis,” March 2004
Speaker — University of Pennsylvania, Parasitology Group: “Understanding amebiasis from the host and pathogen perspective,” November 2004
Speaker — Washington University School of Medicine, Medical Grand Rounds: “Emerging Infectious
Diseases — Preparing for the Unexpected and the Inevitable,” November 2004
Speaker — 7th Annual Conference on Hemophilia, San Juan, Puerto Rico, “Emerging Infections—Preparing for the unexpected and the inevitable,” February 2005
Speaker — NIAID/NIDDK workshop on Humanized Mouse Models of Disease. Washington, DC
Speaker — ASM Biodefense Meeting, Washington DC: “Chimeric SCID-Human Mice to Study Enteric Pathogens,” February 2006
Speaker — MMI/ID Seminar Series: “Molecular Dissection of Entamoeba histolytica Pathogenesis,” March 2006
Speaker — Washington University Reunion Medical Update: “Avian Influenza and Emerging Infectious Diseases,” May 2006
Speaker — Washington University Reunion College: “The Threat of Emerging Infectious Diseases, Avian Influenza and Beyond,” May 2006
Speaker — Pathobiology of human diseases series: Biodefense and the immunogenetics of smallpox vaccination. Washington University, May 2007
Speaker — IGCC-Public Policy and Biological Threats: Training the Next Generation; “Basics of Viral Pathogenesis and Disease.” La Jolla, California, July 2007.
Speaker — 13th Annual Kentucky EPSCoR Statewide Conference. “Perspectives and lessons-learned in building academic team science.” Lexington, Kentucky, October 2007
Speaker — 5th Annual MRCE Meeting, Washington University. “Immunogenetics of Smallpox Vaccination.” St. Louis, MO, October 2007
Speaker — IGCC-Public Policy and Biological Threats: Training the Next Generation; “Basics of Viral Pathogenesis and Disease.” La Jolla, California, July 2008
Speaker — Institute for Public Health, International Public Health Activities at Washington University in St. Louis; Washington University, September 2008
Speaker — Tradeline, Inc., Academic Medical & Health Science Centers 2008; “Key program and facility initiative to grow disease-focused research and funding.” San Francisco, California, October 2009
Speaker — “Fueling Local Economies: Research, Innovation and Jobs,” U.S. Congress Joint Economic Committee Hearing, Washington, DC, June 2010
Speaker — “Challenges for Public Education in the United States and China,” Zuel University, Wuhan, China, April 2011
Speaker – APLU Panel “Continuing Research Amidst Fiscal Restraint,” November 2012
Speaker — Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses: An International Consultative Workshop, Washington, DC, December 2012
Speaker — Dual Use Research of Concern, CICG, Geneva, Switzerland, February 2013
Speaker — AAAS-AAU-APLU-FBI meeting – Setting the Stage: Biological Research in Today’s Global Research Environment, Washington, DC, February 2013
Speaker — National Institutional Biosafety Committees Conference, Seattle, June 2013
Speaker — APLU Annual Meeting — “Working with State Governments: Understanding Higher Education Budgets to Maximize Investments,” November 2014
Speaker — Adelphi University — “Ebola and Beyond: Are We Ready?” November 2014 Presentation — National Science Advisory Board for Biosecurity (NSABB); National Research Council and Institute of Medicine of the National Academies, December 2014
Speaker — AAU Panel “Sustaining the Biomedical Research Enterprise: Mapping a Course for the Future,” April 2015
Speaker — New York State Department of Health Commissioner Medical Grand Rounds: “Mosquito-Borne Infectious Diseases: The Next Frontier,” September 2016
Speaker — SXSWedu Panel — “A Gender Lens: Evolving Equality in Education,” March 2017
Speaker — ACE Panel — “Evolving Gender Equality in HE: University Champions and the United Nations HeForShe Movement,” March 2017
Keynote Speaker — SUNY Undergraduate Research Conference (SURC) — “Far Beyond Test Tubes — The Extraordinary Impact of University Research and Why It Greatly Increases the Value of Your Education,” April 2017
Speaker — G7 University Education for All Conference, Udine, Italy, June 2017
Panelist — NCAA Presidential Panel, Student Athlete Health & Safety Issues, January 2018
Panelist — UC3 Conference, “Setting the Vision and Strategy for Neutrality,” February 2018
Panelist — HeForShe Progress Report: Stories from Four Continents, September 2017
Panel Moderator — APLU Council of Presidents Meeting — “Discussion with FBI: Security Concerns and Research Universities,” June 2018
Panel Moderator — FBI Academia Summit — Preventing, Mitigating and Combating Threats and Risks, September 2018
Panelist — HeForShe Impact Summit, Ending Gender-Based Violence, September 2018
Panelist — Association of Academic Health Centers, “Future of the Relationship between the AHC and the University,” October 2018
Panelist — NAFSA Presidential Panel, Internationalization of Higher Education, November 2018
Speaker — Medical Grand Rounds — “Living with Uncertainty: The Challenge of Dual Use Research and Synthetic Biology,” January 2019
Panelist — American Council on Education (ACE) Annual Meeting, “Science, Security, and Foreign Influence: Insights from Federal Agencies and Higher Education Leadership,” March 2019
PAST RESEARCH SUPPORT
Principal Investigator, U54 AI057160-01, “Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research,” 9/1/03 to 3/1/14, Direct costs: $5,123,000/year
Principal Investigator, NIAID R01 AI-30084, "Molecular Dissection of Entamoeba histolytica pathogenesis,” 7/01/95 to 1/31/2011, Direct costs: $250,000
Co-Investigator, 1UL1RR024992-01 (Kenneth Polonsky, M.D. Principal Investigator) Washington University Institute of Clinical and Translational Sciences (CTSA), Co-Director, Tracking and Evaluation Program, 9/17/07 to 5/31/12, Annual funds $6,818,890
Principal Investigator, Pathways of inflammation and tissue damage in amebiasis. Burroughs Wellcome Scholar in Molecular Parasitology, 7/1/99 to 6/30/06, Total direct costs: $425,000
Principal Investigator, NIAID R01 AI-51621-01, “Structure-Function of Entamoeba alcohol dehydrogenase 2,” 5/01/02 to 3/31/06, Direct costs $200,000/year
Principal Investigator, 1C06RR029841-01, “An Animal Biosafety Level 3 Laboratory for Stony Brook University,” 3/25/10 to 6/30/15, NIH National Center for Research, $14,179,569
CURRENT RESEARCH SUPPORT
Principal Investigator, NSF, Leveraging SUNY LSAMP to Build Better STEM Pathways and Prepare Global STEM Scholars, 7/2011 to 7/2016, Total Award Amount: $2,521,815
Principal Investigator, NSF, The State University of New York (SUNY) LSAMP: Meeting the Grand Challenge of Preparing Students for Successful Transitions into STEM Majors and Beyond, 9/2016 to 9/2021, Total Award Amount: $4 million
CLINICAL TITLE AND RESPONSIBILITIES
Attending physician, Red Medical Service, Barnes Hospital, 1989 to 2007
Attending physician, Infectious Diseases Service, Barnes — Jewish Hospital, 1987 to 2007
Chief Medical Consultant, BarnesCare Travelers Clinic, 1990 to 2009
TEACHING TITLE AND RESPONSIBILITIES
Lecturer, Washington University School of Medicine, 1st-Year Course in Microbiology “Introduction to Tropical Medicine”
Lecturer, Washington University School of Medicine, 2nd-Year Course in Pathophysiology of Infectious Diseases “Bacteremia and Sepsis,” “Protozoa I, Protozoa III,” and “Cases in Tropical Medicine”
Lecturer, Infectious Diseases and the Diagnostic Laboratory Course, “Intestinal Protozoa”
Lecturer, Clinical Infectious Diseases Course, “Diarrheal Diseases,” “Diseases of Travelers,” “Bacteremia and Sepsis,” and “Tropical Diseases”
Lecturer, Lucille P. Markey Special Emphasis Pathway in Human Pathobiology, “Vaccines for Malaria”
Lecturer, Microbial Pathogenesis Course, “MDR genes and pathogenesis”
Lecturer, Molecular Mechanisms of Disease Course, “Vaccines against parasitic diseases”
Instructor, “Case Problems in Cell Biology and Biochemistry”
Instructor, Tropical Medicine Course
Faculty advisor, International Health and Tropical Medicine Forum
Lecturer, Barnes Housestaff Conference, “Diseases of Travelers”
Lecturer, Microbiology 1st year Graduate Student Course, “Protozoan taxonomy and diversity”
Lecturer, Honors Class, “The Global Challenge of Infectious Diseases,” Fall 2012, Stony Brook University
Lecturer, Honors Class, “The 21st Century University,” Fall 2013, Stony Brook University
Lecturer, Honors Class, “The Continuing Challenge of Infectious Diseases,” Spring 2015, Stony Brook University
Lecturer, Honors Class, “Continuing Global Challenges of Infectious Diseases,” Spring 2016, Stony Brook University
Lecturer, Honors Class, “The Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2017, Stony Brook University
Lecturer, Honors Class, “The Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2018, Stony Brook University
Lecturer, Honors Class, “Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2019, Stony Brook University
PUBLICATIONS
Peer-Reviewed
1. Wong, YC; Stanley Jr, SL; Garber, BB. Separation and characterization of neuronal and glial cell populations from embryonic chick cerebra in culture. Anatomischer Anzeiger, 1981; 150:351-373.
2. Stanley Jr, SL; Kehl, O. Ascending paralysis associated with diethylcarbamazine treatment of a M. loa loa infestation—A case report and review of the literature. Tropical Doctor, 1982; 12:16-19.
3. Stanley Jr, SL; Lusk, R. Thoracic actinomycosis presenting as a brachial plexus syndrome. Thorax, 1985: 40:74-75.
4. Powderly, WG; Stanley Jr, SL; Medoff, G. Pneumococcal endocarditis: Report of a series and review of the literature. Review of Infectious Diseases, 1986; 8:786-789.
5. Stanley Jr, SL; Bischoff, JK; Davie, JM. Antigen induced rheumatoid factors: Protein and carbohydrate antigens induce different rheumatoid factor responses. Journal of Immunology, 1987; 139:2936-2942.
6. Stanley Jr, SL; Li, E; Davie, JM. Antigen induced rheumatoid factors: Characterization of monoclonal rheumatoid factors produced after protein and carbohydrate immunization. Molecular Immunology, 1988; 25:285-291.
7. Li, E; Becker, A; Stanley Jr, SL. Use of Chinese hamster ovary cells with altered glycosylation patterns to define the carbohydrate specificity of Entamoeba histolytica adhesion. Journal of Experimental Medicine, 1988, May; 167(5):17251730.
8. Li, E; Becker, A; Stanley Jr, SL. Chinese hamster ovary cells deficient in Nacetylglycosaminyltransferase I activity are resistant to Entamoeba histolytica-mediated cytotoxicity. Infection & Immunity, 1989; 57:812.
9. Stanley Jr, SL; Becker, A; Kunz Jenkins, C; Foster, L; Li, E. Cloning and expression of a membrane antigen of Entamoeba histolytica possessing multiple tandem repeats. Proceedings of the National Academy of Sciences of the USA,1990, Jul 1; 87(13):49764980.
10. Burch, DJ; Li, E; Reed, S; Jackson, TFHG; Stanley Jr, SL. Isolation of a strain specific Entamoeba histolytica cDNA clone. Journal of Clinical Microbiology, 1991; 29:696701.
11. Stanley Jr, SL; Jackson, TFHG; Reed, SL; Calderon, J; Kunz Jenkins, C; Gathiram, V; Li, E. Serodiagnosis of invasive amebiasis using a recombinant Entamoeba histolytica protein. JAMA, 1991, Oct; 266(14):19841986.
12. Stanley Jr, SL; Foster, L; Phillips, N. Molecular analysis of carbohydrate antigen induced monoclonal IgM antiIgG antibodies (rheumatoid factors). Molecular Immunology, 1992, Apr; 29(4):453-61.
13. Stanley Jr, SL; Huizenga, H; Li, E. Isolation and partial characterization of a surface glycoconjugate of Entamoeba histolytica. Molecular & Biochemical Parasitology, 1992; 50:127-138.
14. Stanley Jr, SL; Li, E. Isolation of an Entamoeba histolytica cDNA clone encoding a protein with a putative zinc finger domain. Molecular & Biochemical Parasitology, 1992; 50:185-188.
15. Li, E; Kunz Jenkins, C; Stanley Jr, SL. Isolation and characterization of genomic clones encoding a serinerich Entamoeba histolytica protein. Molecular & Biochemical Parasitology, 1992; 50:355-358.
16. Cieslak, PR; Stanley Jr, SL. Advances in amebiasis: implications for the clinician. Infectious Diseases in Clinical Practice, 1992; 1(3):151-157.
17. Zhang, Y; Li, E; Jackson, TFHG; Zhang, T; Gathiram, V; Stanley Jr, SL. Use of a recombinant 170 kDa surface antigen of Entamoeba histolytica in serodiagnosis of amebiasis, and identification of immunodominant domains of the native molecule. Journal of Clinical Microbiology, 1992, Nov; 30(11):2788-2792.
18. Cieslak, PR; Virgin IV, HW; Stanley Jr, SL. A severe combined immunodeficient (SCID) mouse model for infection with Entamoeba histolytica. Journal of Experimental Medicine, 1992, Dec; 176(6):1605-1609.
19. Myung, K; Burch, DJ; Jackson, TFHG; Stanley Jr, SL. Serodiagnosis of invasive amebiasis using a recombinant Entamoeba histolytica-antigen based ELISA. Archives of Medical Research, 1992; 23(2):285-288.
20. Zhang, Y; Aley, S; Stanley Jr, SL; Gillin, FD. Cysteine-dependent zinc binding by membrane proteins of Giardia lamblia. Infection & Immunity, 1993; 61:520-524.
21. Cieslak, PR; Zhang, T; Stanley Jr, SL. Expression of a recombinant Entamoeba histolytica antigen in a Salmonella typhimurium vaccine strain. Vaccine, 1993; 11:773-776.
22. Zhang, Y; Li, E; Stanley Jr, SL. Entamoeba histolytica: The EHZc3 cDNA clone encodes a zinc-binding protein. Experimental Parasitology, 1993, Aug; 77(1):118-120.
23. Zhang, T; Cieslak, PR; Foster, L; Kunz-Jenkins, C; Stanley Jr, SL. Antibodies to the serine rich Entamoeba histolytica protein (SREHP) prevent amebic liver abscess in severe combined immunodeficient (SCID) mice. Parasite Immunology, 1994, May; 16(5):225-230.
24. Zhang, T; Cieslak, PR; Stanley Jr, SL. Protection of gerbils from amebic liver abscess by immunization with a recombinant Entamoeba histolytica antigen. Infection & Immunity, 1994, Apr; 62(4):1166-70.
25. Yang, W; Li, E; Kairong, T; Stanley Jr, SL. Entamoeba histolytica has an alcohol dehydrogenase homologous to the adhE gene product of Escherichia coli. Molecular & Biochemical Parasitology, 1994; 64:253-260.
26. Zhang, T; Stanley Jr, SL. Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170 kDa adhesin of Entamoeba histolytica. Infection & Immunity, 1994; 62(6):2605-2608.
27. Li, E; Stenson, WF; Kunz-Jenkins, C; Swanson, PE; Duncan, R; Stanley Jr, SL. Entamoeba histolyticainteractions with polarized human intestinal Caco-2 epithelial cells. Infection & Immunity, 1994; 64(11):5112-5119.
28. Stanley Jr, SL; Tian, K; Koester, JP; Li, E. The serine rich Entamoeba histolytica protein (SREHP) is a phosphorylated membrane protein containing O-linked terminal N-acetylglucosamine (O-GlcNAc) residues. Journal of Biological Chemistry, 1995, Feb; 270(8):4121-4126.
29. Stanley Jr, SL; Blanchard, JL; Johnson, N; Foster, L; Kunz-Jenkins, C; Zhang, T; Tian, K; Cogswell, FB. Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African Green Monkey. Vaccine, 1995, Jul; 13(10):947-951.
30. Zhang, T; Li, E; Stanley Jr, SL. Oral immunization with the dodecapeptide repeat of the serine rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. Infection & Immunity. 1995, Apr; 63(4):1349-1355.
31. Stanley Jr, SL; Zhang, T; Rubin, D; Li, E. Role of the amebic cysteine proteinase in amebic liver abscess in severe combined immunodeficient (SCID) mice. Infection & Immunity, 1995, Apr; 63(4):1587-1590.
32. Velazquez, C; Valette, I; Cruz, M; Labra, M-L; Montes, J; Stanley Jr, SL; Calderon, J. Identification of immunogenic epitopes of the 170-kDa subunit adhesin of Entamoeba histolytica in patients with invasive amebiasis. Journal of Eukaryotic Microbiology, 1995, Sep; 42(5):636-641.
33. Li, E; Yang, W-G; Zhang, T; Stanley Jr, SL. Interaction of laminin with Entamoeba histolytica cysteine proteinases and its effect on amebic pathogenesis. Infection & Immunity. 1995, Oct; 63(10):4150-4153.
34. Flores, BM; Stanley Jr, SL; Yong, TS; Ali, M; Diedrich, DL; Torian, BE. Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic Entamoeba histolytica. Journal of Infectious Diseases, 1996, Jan; 173(1):226-231.
35. Yong, TS; Li, E; Clark, D; Stanley Jr, SL. Complementation of a Escherichia coli adhE mutant by the Entamoeba histolyticaEhADH2 gene provides a method for the identification of new anti-amebic drugs. Proceedings of the National Academy of Sciences of the USA, 1996, Jun 25; 93(13):6464-6469.
36. Seydel, KB; Braun, K; Zhang, T; Jackson, TFHG; Stanley Jr, SL. Human anti-amebic antibodies provide protection against amebic liver abscess formation in the SCID mouse. The American Journal of Tropical Medicine & Hygiene, 1996; 55:330-332.
37. Zhang, T; Stanley Jr, SL. Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine rich Entamoeba histolytica protein induces an anti-amebic immune response and protects gerbils from amebic liver disease. Infection & Immunity, 1996, May; 64(5):1526-1531.
38. Seydel, KB; Li, E; Stanley Jr, SL. Human intestinal epithelial cells produce pro-inflammatory cytokines in response to infection in a SCID-HU-INT model of amebiasis. Infection & Immunity, 1997, May; 65(5):1631-1639.
39. Lotter, H; Zhang, T; Seydel, KB; Stanley Jr, SL; Tannich, E. Identification of an epitope on the Entamoeba histolytica 170 kDa-lectin conferring antibody mediated protection against invasive amebiasis. Journal of Experimental Medicine, 1997, May 19 185(10):1793-1801.
40. Ryan, ET; Butterton, JR; Zhang, T; Stanley Jr, SL; Calderwood, SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-V. cholerae antibody responses in mice. Infection & Immunity, 1997, Aug; 65(8):3118-3125.
41. Seydel, KB; Zhang, T; Stanley Jr, SL. Neutrophils play a critical role in early resistance to amebic liver abscess in SCID mice. Infection & Immunity, 1997, Sep; 65(9):3951-3953.
42. Zhang, T; Stanley Jr, SL Expression of the serine rich Entamoeba histolytica protein (SREHP) in the avirulent vaccine strain Salmonella typhi TY2x4297 cya crp asd: Safety and immunogenicity in mice. Vaccine, 1997, Aug-Sep; 15(12-13): 1319-1322.
43. Marinets, A; Zhang, T; Guillen, N; Gounon, P; Bohle, B; Vollman, U; Scheiner, O; Wiedermann, G; Stanley Jr, SL; Duchene, M. Protection against invasive amoebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica. Journal of Experimental Medicine, 1997; 186:1557-1565.
44. Wang, L; Calderon, J; Stanley Jr, SL. Identification of B cell epitopes in the serine rich Entamoeba histolytica protein. The American Journal of Tropical Medicine & Hygiene, 1997, Dec; 57(6):723-726.
45. Stanley Jr, SL; Jackson, TFHG; Foster, L; Singh, S. Longitudinal study of the antibody response to recombinant Entamoeba histolytica antigens in patients with amebic liver abscess. The American Journal of Tropical Medicine & Hygiene, 1998, Apr; 58(4):414-416.
46. Sultan, F; Jin-L-l; Jobling, MG; Holmes, RK; Stanley Jr, SL. Mucosal immunogenicity of a holotoxin-like molecule containing the serine rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infection & Immunity, 1998, Feb; 66(2):462-468.
47. Seydel, KB; Zhang, T; Champion, GA; Fichtenbaum, C; Swanson, PE; Tzipori, S; Griffiths, JK; Stanley Jr, SL. Cryptosporidium parvum infection induces human TNF and IL-8 production from human intestinal xenografts in SCID mice. Infection & Immunity, 1998; 66:2379-2398.
48. Seydel, KB; Stanley Jr, SL. Entamoeba histolytica induces host cell death in amebic liver abscess by a non-Fas, non-TNF-dependent pathway of apoptosis. Infection & Immunity, 1998 Jun; 66(6):2980-2983.
49. Seydel, KB; Li, E; Zhang, Z; Stanley Jr, SL. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology,1998, Dec; 115(6):1446-1453.
50. Temesvari, LA; Harris, EN; Stanley Jr, SL; Cardelli, JA. Early and late endosomal compartments of Entamoeba histolytica are enriched in cysteine proteinases, acid phosphatases and several Ras-related Rab GTPases. Molecular & Biochemical Parasitology, 1999; 103:225-241.
51. Zhang, T; Stanley Jr, SL. DNA vaccination with the serine rich Entamoeba histolytica protein (SREHP) prevents amebic liver abscess in rodent models of disease. Vaccine, 1999, Dec 10; 18(9-10):868-874.
52. Seydel, KB; Smith, SJ; Stanley Jr, SL. Interferon-gamma and nitric oxide are required for host defense in a murine model of amebic liver abscess. Infection & Immunity, 2000; 68:400-402.
53. Lotter, H; Khajawa, F; Stanley Jr, SL; Tannich, E. Protection of gerbils from amebic liver abscess by vaccination with a 25 mer peptide derived from the “cysteine-rich” region of the Entamoeba histolytica galactose-specific adherence lectin. Infection & Immunity, 2000; 68:4416-4421.
54. Zhang, Z; Yan, L; Wang, L; Seydel, KB; Li, E; Ankri, S; Mirelman, D; Stanley Jr, SL. Emtamoeba histolytica cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amebiasis. Molecular Microbiology, 2000, Aug; 37(3):542-548.
55. Zhang, Z; Jin, L; Champion, G; Seydel, KB; Stanley Jr, SL. Shigella infection in SCID-HU-INT mice: role for neutrophils in containing bacterial dissemination in human intestine. Infection & Immunity, 2001; 69:3240-3247.
56. Stenson, W; Zhang, Z; Riehl, T; Stanley Jr, SL. Amebic infection induces cyclooxygenase-2 (COX-2) production in human intestine. Infection & Immunity, 2001; 69:3382-3388.
57. Espinosa, A; Yan, L; Zhang, Z; Foster. L; Clark, D; Li, E; Stanley Jr, SL. The bifunctional Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) protein is necessary for amebic growth and survival and requires an intact C-terminal domain for both alcohol dehydrogenase and acetaldehyde dehydrogenase activity. Journal of Biological Chemistry, 2001, Jun 8; 276(23):20136-20143.
58. Babcock, HM; Ritchie, DJ; Christiansen, E; Starlin, R; Little, R; Stanley Jr, SL. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clinical Infectious Diseases, 2001, May 1; 32(9):1373-1375.
59. Yan, L; Stanley Jr, SL. Blockade of caspases inhibits amebic liver abscess formation in a mouse model of disease. Infection & Immunity, 2001; 69:7911-7914.
60. Zhang, Z; Duchene, M; Stanley Jr, SL. A monoclonal antibody to the amebic lipophosphoglycan/proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with Entamoeba histolytica. Infection & Immunity, 2002; 70:5873-5876.
61. Zhang, Z; Mahajan, S; Zhang, X-C; Stanley Jr, SL. Tumor necrosis factor-α is a key mediator of the gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. Infection & Immunity, 2003; 71:5355-5359.
62. Zhang, X-C; Zhang, Z; Alexander D; Bracha, R; Mirelman, D; Stanley Jr, SL. Expression of amoebapores is required for full expression of Entamoeba histolytica virulence in amebic liver abscess, but is not necessary for the induction of inflammation or tissue damage in amebic colitis. Infection & Immunity, 2004; 72:678-683.
63. Zhang, Z; Stanley Jr, SL. Stereotypic and specific elements of the human colonic response to Entamoeba histolytica and Shigella flexneri infection. Cellular Microbiology, 2004, Jun; 6(6):535-564.
64. Espinosa, A; Clark, DC; Stanley Jr, SL. Entamoeba histolytica Alcohol Dehydrogenase 2 (EhADH2) as a target for antiamoebic agents. Journal of Antimicrobial Chemotherapy, 2004, Jul; 54(1):56-59.
65. Chen, M; Li, E; Stanley Jr, SL. Structural analysis of the acetaldehyde dehydrogenase activity of Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2), a member of the ADHE enzyme family. Molecular & Biochemical Parasitology, 2004; 137:201-205.
66. Davis, PH; Zhang, Z; Chen, M; Zhang, XC; Chakraborty, S; Stanley Jr, SL. Identification and characterization of a family of Bsp-A like surface proteins of Entamoeba histolytica with novel leucine rich repeats. Molecular & Biochemical Parasitology, 2006; 145:111-116.
67. Pelosoff, L; Davis, PH; Zhang, Z; Zhang, XC; Stanley Jr, SL. Coordinate but disproportionate activation of apoptotic, regenerative, and inflammatory pathways characterizes the liver response to acute amebic infection. Cellular Microbiology, 2006, Mar; 8(3):508-522.
68. Stanley Jr, SL. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease. Seminars in Hematology, 2006, Apr; 43(3) Supplement: S17-S22.
69. Davis, P; Zhang, X; Guo, J; Townsend, RR; Stanley Jr, SL. Comparative proteomic analysis of two Entamoeba histolytica stains with different virulence phenotypes identifies peroxiredoxin as an important component of amebic virulence. Molecular Microbiology, 2006; 61:1523-1532.
70. Ludlam, CA; Powderly, WG; Bozzett, S; Diamond, M; Koerper, MA; Kulkarni, R; Ritchie, B; Siegel, J; Simmonds, P; Stanley Jr, SL; Tapper, ML; von Depka, M. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet, 2006, Jan 21; 367(9506):252-261.
71. Davis, PA; Schulz, J; Stanley Jr, SL. Transcriptomic comparison of two Entamoeba histolytica stains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin. Molecular & Biochemical Parasitology, 2007, Jan; 151(1):118-128.
72. Stanley Jr, SL; Frey, SE; Taillon-Miller, P; Guo, J; Miller RD; Koboldt, DC; Elashoff, M; Christensen, R; Saccone, NL; Belshe, RB. The Immunogenetics of Smallpox Vaccination. Journal of Infectious Diseases, 2007, Jul 15; 196(2): 212-219.
73. Lawrence, SJ; Lottenbach, KR; Newman, FK; Buller, RM; Bellone, CJ; Chen, JJ; Cohen, GH; Eisenberg, RJ; Belshe, RB; Stanley Jr, SL; Frey, SE. Antibody response to vaccinia membrane proteins after smallpox vaccination. Journal of Infectious Diseases, 2007; 196(2):220-229.
74. Melendez-Lopez SG; Herdman, S; Hirata K; Choi, MH; Choe, Y; Craik, C; Caffrey, CR; Hansell, E; Chavez-Munguia, B; Chen, YT; Roush, WR; Mckerrow, J; Eckmann, L; Guo, J; Stanley Jr, SL; Reed, SL. Use of recombinant Entamoeba histolyticacysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. Eukaryotic Cell, 2007, Jul; 6(7):1130-1136.
75. Bullok, KE; Maxwell, D; Kesarwala, AH; Gammon, S; Prior, JL; Snow, M; Stanley, S; Piwnica-Worms, D. Biochemical and in vivo characterization of a small membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry, 2007, Apr 3; 46 (13): 4055-4065.
76. Snow, M; Chen, M; Guo, J; Atkinson, J; Stanley Jr, SL. Differences in complement mediated killing of Entamoeba histolytica between men and women—an explanation for the increased susceptibility of men to invasive amebiasis? American Journal of Tropical Medicine and Hygiene. 2008, June; 78 (6): 922-923.
77. Sarder, P; Nehorai, A; Davis, PH; Stanley Jr, SL. Estimating gene signals from noisy microarray images. IEEE Transactions on NanoBioscience. 2008, June, 7(2):142-153.
78. Sperandio, B., Regnault B., Guo J., Zhang Z, Stanley SL Jr., Sansonetti PJ, Pedron T. Virulent Shigella flexneri subverts the host innate immune response through the manipulation of antimicrobial peptide gene expression. Journal of Experimental Medicine, 2008, 205:1121-32.
79. Davis, P; Chen, M; Zhang, X; Clark, CG; Townsend, RR; Stanley Jr, SL. Proteomic Comparison of Entamoeba histolyticaand Entamoeba dispar and the Role of E.histolyticaAlcohol Dehydrogenase 3 in Virulence. PLOS Neglected Tropical Diseases, 2009, 3 (4): e415. Epub 2009 Arp 14. PMID: 19365541
80. Biller L, Davis PH, Tillack M, Matthiesen J, Lotter H, Stanley Jr, SL, Tannich E, Bruchhaus I. Differences in the transcriptome signatures of two genetically related Entamoeba histolytica cell lines derived from the same isolate with different pathogenic properties. BMC Genomics 2010 Jan 26;11:63. PMID: 20102605
81. Otero K, Turnbull IR, Poliani PL, Vermi W, Cerutti E, Aoshi T, Tassi I, Takai T, Stanley Jr, SL, Miller M, Shaw AS, Colonna M. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol. 2009 Jul;10(7):734-43 Epub 2009 Jun 7. PMID: 19503107
Reviews and Invited Publications
1. Stanley Jr, SL; Davie, JM. “Production and function of rheumatoid factors in the normal immune response” Contribution to Microbiology Immunology, 1989; 11:151-187.
2. Li, E; Stanley Jr, SL. “The role of newer antibiotics in gastroenterology.” Gastroenterology Clinics of North America, 1992; 21: 613-631.
3. Stanley Jr, SL; Burch, DJ; Cieslak, P. “New diagnostic techniques in amebiasis.” L abMedica International 1992; 9:7-10.
4. Stanley Jr, SL. “Amebiasis,” in Conn's Current Therapy. R.E. Rakel, Ed. W.B. Saunders Company, Philadelphia, pp. 60-62, 1993.
5. Stanley Jr, SL; Li, E. “Pathophysiology of Amebiasis.” Seminars in Gastrointestinal Disease 1993; 4:214-223.
6. Stanley Jr, SL; Virgin, IV, HW. “Scid mice as models for helminth and protozoan diseases.” Parasitology Today 1993; 9:406-412.
7. Stanley Jr, SL. "Susceptibility testing and acquired drug resistance in parasitic diseases", in Handbook of Clinical Microbiology, Washington, DC, P. R. Murray, Ed. ASM Press. pp. 1424-1427, 1995.
8. Li, E; Stanley Jr, SL. “Parasitic diseases of the GI tract.” Current Opinion in Gastroenterology, 1995; 11:63-68.
9. Li, E; Stanley Jr, SL. “Amebiasis.” Gastroenterology Clinics of North America, 1996; 25:471-492.
10. Seydel, K; Stanley Jr, SL. “Scid mouse models for parasitic diseases.” Clinical Microbiology Review, 1996; 9:126-134.
11. Stanley Jr, SL. “Progress in a vaccine for amebiasis.” Parasitology Today. 1996; 12:7-14.
12. Sultan, F; Stanley Jr, SL. "Amebiasis" in Current Diagnosis 9, edited by Conn, RB, Borer, WZ, and Snyder, JW. Philadelphia, W.B. Saunders, pp. 225-227, 1997.
13. Stanley Jr, SL. “Progress towards development of a vaccine for amebiasis.” Clinical Microbiology Review, 1997, Oct; 10(4):637-649.
14. Stanley Jr, SL. “Malaria vaccines: Are seven antigens better than one?” Lancet 352 (9135):1163-1164), 1998.
15. Stanley Jr, SL. “Advice to travelers” in Textbook of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1145-1159, 1999.
16. Stanley Jr, SL. “Advice to travelers” in Atlas of Gastroenterology, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 127-138, 1999.
17. Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Textbook of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 2423-2441, 1999.
18. Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Atlas of Gastroenterology, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 516-526, 1999.
19. Stanley Jr, SL. “Prevention of amebiasis and potential of new interventions.” In Amebiasis, edited by Ravdin, J.I. London, Imperial College Press, pp. 137-163, 2000.
20. Stanley Jr, SL; Zhang, T; Seydel, KB. “Animal models of amebiasis.” In Handbook of Animal Models of Infection, edited by Zak, O, and Sande, M. London, Academic Press, pp. 859-865,2000.
21. Stanley Jr, SL. “Extraintestinal amebiasis.” In Current Therapy for Infectious Diseases, Edited by Schlossberg, D., St. Louis, Mosby, Inc. pp. 693-695, 2001.
22. Stanley Jr, SL; Li, E. “Amoebiasis.” In Encyclopedia of Life Sciences. London, Macmillan Reference Limited, 2001.
23. Stanley Jr, SL. “Pathophysiology of amebiasis.” Trends in Parasitology (formerly Parasitology Today). 2001; 17:280-285.
24. Stanley Jr, SL; Reed, SL. “Entamoeba histolytica: parasite-host interactions.” American Journal of Physiology – Gastrointestinal & Liver Physiology. 2001, Jun; 280: G1049-G1054.
25. Stanley Jr, SL. “Protective immunity to amebiasis: New insights and new challenges.” Journal of Infectious Diseases, 2001; 184:504-506.
26. Stanley Jr, SL. “Amebiasis.” Pier Module. 2002. www.pier
27. Stanley Jr, SL. “Pathways for amebic induction of inflammation and programmed cell death.” Journal of Parasitology, 2003; 89:S182-S188.
28. Stanley Jr, SL. “Amoebiasis.” Lancet, 2003. 361:1025-34.
29. Stanley Jr, SL. “Advice to travelers” in Textbook of Gastroenterology, 4th Edition, edited by Yamada,T. Philadelphia, Lippincott-Raven, pp. 1120-1134, 2003.
30. Stanley Jr, SL. “Advice to travelers” in Atlas of Gastroenterology, 3rd Edition, edited by Yamada,T. Philadelphia, Lippincott-Raven, pp. 153-162, 2003.
31. Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Textbook of Gastroenterology, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven. pp. 2589-2607, 2003.
32. Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Atlas of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp: 749-760, 2003.
33. Davis, P; Stanley Jr, SL. “Breaking the species barrier: the use of mouse human chimeras to study human infectious diseases.” Cellular Microbiology, 2003. 5:849-860.
34. Stanley Jr, SL. “Antiparasitic agents.” In Infectious Diseases, 2nd Edition, edited by Cohen, J., and Powderly, W. London, Mosby, pp. 1941-1960, 2004.
35. Stanley Jr, SL. “Amebiasis.” In Encyclopedia of Gastroenterology. San Diego, Elsevier, pp. 52-57, 2004.
36. Stanley Jr, SL. “The Entamoeba histolytica genome: Something old, something new, something borrowed, and sex too?” Trends in Parasitology, 2005, Oct; 21(10):451-3.
37. Phillips, M; Stanley Jr, SL. “Chemotherapy of protozoal infections.” In Goodman and Gilman’s Pharmacological Basis of Therapeutics, 11th Edition, edited by Lazo, JS, Parker, K, Brunton, LL, Goodman, LS and Gilman, A. New York, McGraw Hill, 2005.
38. Snow, M; Stanley Jr, SL. “Recent progress in vaccines for amebiasis.” Archives of Medical Research, 2006; 37:280-287.
39. Stanley, Jr, SL. “Vaccines for amoebiasis: barriers and opportunities.” Parasitology, 2006; 133:S81-86.
40. Stanley Jr, SL. “Antiparasitic agents” in Infectious Diseases, 3rd Edition, edited by Cohen, J, Powderly, W., Opal, S.M., Mosby, Chapter 150, 2010.
41. Phillips, M; Stanley Jr, SL. “Chemotherapy of protozoal infections” in Goodman and Gilman’s
Pharmacological Basis of Therapeutics, 12th Edition, edited by Brunton, LL, Chabner, B, Knollmann, B, New York, McGraw Hill, in press.
42. Stanley Jr, SL. “Amebiasis and infection with free-living amebas” in Harrison’s Principles of InternalMedicine, 18th Edition, edited by Longo, D., Fauci, A., Kasper, D., Hauser, S., Jameson, J., Loscalzo, J. NewYork, McGraw Hill, 2011.
PATENTS
US Patent 5,130,147: Entamoeba histolytica Immunogenic protein and cDNA clone
Significance: patent of the SREHP cDNA clone; recombinant SREHP is a major vaccine candidate for amebiasis, and a reagent utilized in prototype diagnostic tests.
Inventor: Samuel L. Stanley Jr. and Ellen Li
Assignee: Washington University, St. Louis
US Patent 5,275,935: Amebic glycoconjugate and monoclonal antibody
Significance: patent of the amebic glycoconjugate, a major surface antigen of amebae and a monoclonal antibody, CC 8.6 which recognizes this antigen. Possible uses in diagnostic kits.
Inventor: Samuel L. Stanley Jr. and Ellen Li
Assignee: Washington University, St. Louis
US Patent 5,807,000: Method of screening anti-amebic compounds
Significance: Describes the use of mutant E. coli strains complemented with amebic antigens to screen compounds for anti-amebic activity.
Inventor: Samuel L. Stanley Jr.
Assignee: Washington University, St. Louis